Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

earch, organizational development and planning related to the return of full rights for quizartinib.

Other expenses (net) were $10.3 million and $3.6 million for the nine months ended September 30, 2013 and 2012, respectively.  The increase of $6.7 million was primarily due to the change in fair value of the Company's stock warrant liabilities, which is driven by the change in fair value of the underlying preferred or common securities.

At September 30, 2013, the Company had cash and equivalents of $78.9 million, compared to $17.5 million at December 31, 2012.  The increase of $61.4 million was primarily due to the completion of an initial public offering that raised net proceeds of $58.1 million and to the completion of a concurrent private offering that raised net proceeds of $25.1 million, less cash used to fund operations.

The Company expects its research and development expense to increase as it prepares for the initiation of the Phase 3 clinical trial of quizartinib in relapsed or refractory AML patients, which is expected to begin early in 2014.  Under the base case operating plan, which assumes that the FDA will require a randomized, controlled Phase 3 clinical trial for an NDA submission, the Company currently expects cash and cash equivalents to be sufficient to fund this trial and operations through the receipt of top line data from the Company's Phase 3 trial in approximately 326 relapsed/refractory AML patients. 

Conference Call and Webcast
A conference call hosted by the Ambit management team will be webcast live today at 2pm PT or 5pm ET and can be accessed by dialing 866-436-9172 for domestic callers and 630-691-2760 for international callers. Please specify that you would like to join the "Ambit Third Quarter 2013 Earnings Conference Call" and reference conference ID number 35424048.  If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday,
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014 ... analyze and research medicinal plants and therapeutic derivatives ... industry, health professionals, and researchers about the challenges ... (Logo: http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The ...
(Date:1/14/2014)... WESTBOROUGH, Mass. , Jan. 14, 2014  RXi ... on discovering, developing and commercializing innovative therapies addressing ... announced that it received the Notice of Allowance ... on its unique self-delivering RNAi compounds (sd-rxRNA®), for ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... (Nasdaq: ARNA ) today announced it will report ... closes on Monday, May 11, 2009. That same afternoon, Jack ... Hoffman, Arena,s Vice President, Finance and Chief Financial Officer, will ... p.m. Pacific Time) to discuss the financial results for the ...
... On Thursday, May 7, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central ... CTIC) management team will host a conference call to discuss the Company,s ... Conference Call Numbers, ... 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time, ...
... Biotech Inc. (TSX:ONC, NASDAQ: ONCY ) ("Oncolytics" or ... three-month period ended March 31, 2009. , "The first ... very positive results in several of our combination REOLYSIN(R) ... of Oncolytics. "We continue to report clinical benefit in ...
Cached Biology Technology:Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 2Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009 3Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7 2Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 2Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 3Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 4Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 5Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 6Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 7Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results 8
(Date:4/22/2014)... Biotechnology scientists must be aware of the broad ... guidelines, according to a new paper from Rice University,s ... current issue of the journal Regenerative Medicine , ... Supreme Court ruling in the case Association for Molecular ... are unpatentable. The court case and rulings garnered discussion ...
(Date:4/22/2014)... Scientists at the University of Massachusetts Amherst and ... this week report that they have discovered a new ... of the Negro River in the Amazonia State of ... with Adlia Nogueira and Jos Antnio Alves-Gomes of INPA, ... of the journal Proceedings of the Natural Sciences ...
(Date:4/22/2014)... of nanotechnology researchers at the University of Kentucky has ... arrays using RNA. , The research, led by ... in Nanobiotechnology at the UK College of Pharmacy and ... "RNA as a Boiling-Resistant Anionic Polymer Material To Build ... Emil F. Khisamutdinov and Daniel L. Jasinski. , The ...
Breaking Biology News(10 mins):New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3New electric fish genus and species discovered in Brazil's Rio Negro 2RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures 2
... from the Department of Defense will allow North Carolina ... Institute of Research to further test the effectiveness of ... infections. The two-and-a-half-year project will show the efficacy ... and Dr. John Cavanagh against different types of animal ...
... McMaster University is establishing the first NVIDIA CUDA ... of only twelve worldwide, will teach electrical and ... processing resources available in graphics processing units (GPU) ... CUDA is a parallel computing architecture that enables ...
... antibacterial ingredient in some soaps, toothpastes, odor-fighting socks, and ... new treatment for a parasitic disease that affects almost ... the guiding light for future development of drugs for ... Chemistry . In the study, Rima McLeod and ...
Cached Biology News:NC State research grant will help military combat infections 2McMaster, NVIDIA establish first CUDA Teaching Centre in Canada 2
...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
...
... SureLINK HRP Conjugation Kits are based ... conjugates that are consistent and reproducible. ... to conjugate your protein or antibody, ... storage buffer. Activated HRP is ...
Biology Products: